BioCardia (NASDAQ:BCDA – Get Free Report) and Tevogen Bio (NASDAQ:TVGN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Analyst Recommendations
This is a summary of current ratings for BioCardia and Tevogen Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 0 | 1 | 0 | 3.00 |
| Tevogen Bio | 0 | 0 | 1 | 0 | 3.00 |
BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 924.59%. Tevogen Bio has a consensus target price of $4.20, suggesting a potential upside of 206.57%. Given BioCardia’s higher probable upside, research analysts plainly believe BioCardia is more favorable than Tevogen Bio.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -1,999.77% | N/A | -278.27% |
| Tevogen Bio | N/A | -387.78% | 434.75% |
Insider and Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. 20.0% of BioCardia shares are held by company insiders. Comparatively, 56.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares BioCardia and Tevogen Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $428,000.00 | 10.38 | -$11.57 million | ($7.05) | -0.35 |
| Tevogen Bio | N/A | N/A | -$70,000.00 | N/A | N/A |
Tevogen Bio has lower revenue, but higher earnings than BioCardia.
Risk & Volatility
BioCardia has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.
Summary
BioCardia beats Tevogen Bio on 5 of the 9 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
